Serum MHRT expression was elevated in CAD and correlated positively with the Gensini score, and HIIT significantly improved cardiopulmonary function and quality of life in CAD patients accompanied by a marked reduction in serum MHRT levels, suggesting MHRT may serve as a potential biomarker for monitoring HIIT efficacy.
Key Findings
Results
Serum MHRT expression was elevated in CAD patients compared to non-CAD volunteers.
A total of 88 CAD patients were enrolled along with non-CAD volunteers recruited as controls.
Serum MHRT levels were assessed using quantitative reverse transcription PCR (qRT-PCR).
The predictive value of MHRT in CAD was evaluated using ROC curves and logistic regression analysis.
Results
Serum MHRT levels correlated positively with the Gensini score, a measure of coronary artery disease severity.
The association between MHRT levels and the Gensini score was assessed using Pearson's correlation analysis.
A positive correlation was found between serum MHRT expression and the Gensini score.
This suggests higher MHRT levels are associated with more severe coronary artery disease.
Results
HIIT intervention improved cardiopulmonary function indicators and quality-of-life scores in CAD patients.
Cardiopulmonary function indicators increased after the HIIT intervention in the HIIT group.
Quality-of-life scores also increased after the HIIT intervention.
The study compared a HIIT intervention group to assess changes in these outcomes.
Results
Serum MHRT levels decreased after HIIT intervention and were lower in clinically effective responders than in non-responders.
Serum MHRT decreased after the HIIT intervention in CAD patients.
MHRT levels were lower in the clinically effective group than in the ineffective group.
This differential expression pattern supports MHRT as a potential biomarker for monitoring HIIT treatment efficacy.
Results
MHRT demonstrated predictive value for CAD diagnosis as assessed by ROC curve analysis and logistic regression.
ROC curves were used to evaluate the diagnostic predictive value of serum MHRT for CAD.
Logistic regression analysis was also applied to assess MHRT's predictive potential.
These analyses were conducted in the context of 88 enrolled CAD patients compared to non-CAD volunteers.
What This Means
This research suggests that a molecule called MHRT (Myosin Heavy-Chain-Associated RNA Transcript), which can be measured in the blood, is elevated in patients with coronary artery disease (CAD) and reflects how severe the disease is. The study enrolled 88 CAD patients and compared them to healthy volunteers, finding that higher blood levels of MHRT were associated with more extensive coronary artery blockage as measured by the Gensini score, a standard clinical tool for rating disease severity.
The study also investigated whether a structured exercise program called High-Intensity Interval Training (HIIT) could benefit CAD patients and whether MHRT levels would reflect that benefit. After completing HIIT, patients showed improvements in cardiopulmonary (heart and lung) function and quality of life. Importantly, their blood MHRT levels dropped following the exercise program, and patients who responded well clinically had lower MHRT levels than those who did not respond as well.
This research suggests that MHRT could serve as a useful blood-based biomarker — a measurable indicator — both for identifying CAD severity and for tracking how well a patient is responding to HIIT rehabilitation. This could potentially help clinicians objectively monitor the effectiveness of cardiac exercise programs, which are an important part of recovery for heart disease patients.
Zhao Y, Zhou X, Yuan G, Yang J. (2026). Myosin Heavy-Chain-Associated RNA Transcript for Cardiopulmonary Recovery Prediction in High-Intensity Interval Training for Coronary Artery Disease.. Journal of visualized experiments : JoVE. https://doi.org/10.3791/71478